Free tool
FAERS Monitor: Angiomax
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020873 or its brand name (Angiomax, Bivalirudin). Reports on generic versions are filed under their own applications.
Reports
992
Serious
906
91% of reports
Hospitalization
419
Death reported
155
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective200
- off label use114
- haemorrhage91
- heparin-induced thrombocytopenia76
- gastrointestinal haemorrhage45
- thrombosis44
- vascular stent thrombosis40
- acute myocardial infarction36
- hypotension33
- thrombosis in device33
- product use issue29
- cardiac arrest25
- haemorrhage intracranial25
- thrombocytopenia25
- deep vein thrombosis23
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 21 |
| 2005 | 17 |
| 2006 | 17 |
| 2007 | 7 |
| 2008 | 13 |
| 2009 | 23 |
| 2010 | 24 |
| 2011 | 22 |
| 2012 | 29 |
| 2013 | 31 |
| 2014 | 46 |
| 2015 | 27 |
| 2016 | 32 |
| 2017 | 26 |
| 2018 | 29 |
| 2019 | 47 |
| 2020 | 65 |
| 2021 | 84 |
| 2022 | 93 |
| 2023 | 93 |
| 2024 | 100 |
| 2025 | 91 |
| 2026 | 55 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,167 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vascular stent thrombosisSignal | 40 | 425.1 | 312.8 | 16,180 |
| heparin-induced thrombocytopeniaSignal | 76 | 332.2 | 267.1 | 24,386 |
| thrombosis in deviceSignal | 33 | 215.6 | 153.9 | 6,769 |
| haemorrhage intracranialSignal | 25 | 35.5 | 24.1 | 804 |
| acute myocardial infarctionSignal | 36 | 25.9 | 18.8 | 838 |
| haemorrhageSignal | 91 | 18.5 | 15.2 | 1,493 |
| thrombosisSignal | 44 | 11.6 | 8.7 | 417 |
| gastrointestinal haemorrhageSignal | 45 | 11.4 | 8.6 | 419 |
| deep vein thrombosisSignal | 23 | 7.5 | 5.0 | 124 |
| cardiac arrestSignal | 25 | 6.4 | 4.4 | 109 |
| thrombocytopeniaSignal | 25 | 4.7 | 3.2 | 70 |
| hypotensionSignal | 33 | 3.5 | 2.5 | 57 |
| product use issueSignal | 29 | 3.3 | 2.3 | 44 |
| drug ineffectiveSignal | 200 | 3.2 | 2.8 | 324 |
| off label useSignal | 114 | 2.8 | 2.3 | 132 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.